TY - JOUR
T1 - Use of primary bariatric surgery among patients with obesity and diabetes. Insights from the Diabetes Collaborative Registry
AU - Jain, Priya
AU - Hejjaji, Vittal
AU - Thomas, Merrill B.
AU - Garcia, Raul Angel
AU - Kennedy, Kevin F.
AU - Goyal, Abhinav
AU - Sperling, Laurence
AU - Das, Sandeep R.
AU - Hafida, Samar
AU - Enriquez, Jonathan R.
AU - Arnold, Suzanne V.
N1 - Funding Information:
VH, MBT, and RAG, are supported by the National Heart, Lung, and Blood Institutes of Health Under Award Number T32HL110837; the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors declare no competing interests.
Funding Information:
VH, MBT, and RAG are supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health (T32HL110837). DCR was previously funded by AstraZeneca and Boehringer Ingelheim and is currently managed by Veradigm. Corporate sponsors had no role in data analysis or interpretation, manuscript development, or in publication review or approval for this study.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022
Y1 - 2022
N2 - Despite its cardiometabolic benefits, bariatric surgery has historically been underused in patients with obesity and diabetes, but contemporary data are lacking. Among 1,520,182 patients evaluated from 2013 to 2019 within a multicenter, longitudinal, US registry of outpatients with diabetes, we found that 462,033 (30%) met eligibility for bariatric surgery. After a median follow-up of 854 days, 6310/384,859 patients (1.6%) underwent primary bariatric surgery, with a slight increase over time (0.38% per year [2013] to 0.68% per year [2018]). Patients who underwent bariatric surgery were more likely to be female (63% vs. 56%), white (87% vs. 82%), have higher body mass indices (42.1 ± 6.9 vs. 40.6 ± 5.9 kg/m2), and depression (23% vs. 14%; p < 0.001 for all). Over a median (IQR) follow-up after surgery of 722 days (364–993), patients who underwent bariatric surgery had lost an average of 11.8 ± 18.5 kg (23% of excess body weight), 10.2% were on fewer glucose-lowering medications, and 8.4% were on fewer antihypertensives. Despite bariatric surgery being safer and more accessible over the past two decades, less than one in fifty eligible patients with diabetes receive this therapy.
AB - Despite its cardiometabolic benefits, bariatric surgery has historically been underused in patients with obesity and diabetes, but contemporary data are lacking. Among 1,520,182 patients evaluated from 2013 to 2019 within a multicenter, longitudinal, US registry of outpatients with diabetes, we found that 462,033 (30%) met eligibility for bariatric surgery. After a median follow-up of 854 days, 6310/384,859 patients (1.6%) underwent primary bariatric surgery, with a slight increase over time (0.38% per year [2013] to 0.68% per year [2018]). Patients who underwent bariatric surgery were more likely to be female (63% vs. 56%), white (87% vs. 82%), have higher body mass indices (42.1 ± 6.9 vs. 40.6 ± 5.9 kg/m2), and depression (23% vs. 14%; p < 0.001 for all). Over a median (IQR) follow-up after surgery of 722 days (364–993), patients who underwent bariatric surgery had lost an average of 11.8 ± 18.5 kg (23% of excess body weight), 10.2% were on fewer glucose-lowering medications, and 8.4% were on fewer antihypertensives. Despite bariatric surgery being safer and more accessible over the past two decades, less than one in fifty eligible patients with diabetes receive this therapy.
UR - http://www.scopus.com/inward/record.url?scp=85137061864&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137061864&partnerID=8YFLogxK
U2 - 10.1038/s41366-022-01217-w
DO - 10.1038/s41366-022-01217-w
M3 - Article
C2 - 36008680
AN - SCOPUS:85137061864
SN - 0307-0565
JO - International Journal of Obesity
JF - International Journal of Obesity
ER -